Seller record · Telehealth service

Harper Meds

By Paul Harris, Standards EditorRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 2 of 8 criteria. S3, pharmacy identification: No filling pharmacy is named. The home page refers to a partner pharmacy, and the terms to the operating company or one of its partner pharmacies. 1 more criterion also fails; see the table below.

At a glance

Harper MedsTelehealth service

6/8criteria passed

Price: Compounded semaglutide or tirzepatide program from $149 a month
Sells: compounded semaglutide, compounded tirzepatide
FDA letters: 1 on file

Visit Harper Meds See all eight dispositions

Telehealth service. Passes 6 of 8 criteria. Recorded against Standard v1.1.

A telehealth service selling compounded semaglutide and tirzepatide through the Wasef Health and Beluga Health physician networks, with one monthly price covering the consultation, medication and shipping. Care starts with an online questionnaire, and no pharmacy is named.

Operating entity Nexus Health Solutions LLC

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	Harper Meds' website; Harper Meds' terms of service page
S2	Prescription gating	PASS	Harper Meds' website
S3	Pharmacy identification	FAIL	Harper Meds' website; Harper Meds' terms of service page
S4	Compounding disclosure	PASS	Harper Meds' website
S5	Analytical documentation	FAIL	Harper Meds' website; Harper Meds' terms of service page; Harper Meds' privacy policy
S6	Business address	PASS	Harper Meds' privacy policy; Harper Meds' terms of service page
S7	Price disclosure	PASS	Harper Meds' website
S8	Enforcement status	PASS	FDA's website; FDA warning letter 728281

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSThe decision to prescribe lies solely with Wasef Health and Beluga Health clinicians, and a licensed US medical doctor reviews each questionnaire before any prescription.Source: Harper Meds' website; Harper Meds' terms of service page.

S2PASSThe home page puts the questionnaire first and a doctor's review second, and its answers say nothing is charged until a doctor approves the prescription, with any payment held at checkout until the prescription goes to the pharmacy.Source: Harper Meds' website.

S3FAILNo filling pharmacy is named. The home page refers to a partner pharmacy, and the terms to the operating company or one of its partner pharmacies.Source: Harper Meds' website; Harper Meds' terms of service page.

S4PASSThe home page names compounded semaglutide and tirzepatide and states that the medications themselves are not FDA-approved.Source: Harper Meds' website.

S5FAILNo certificate of analysis or lot document is published on the home page, in the terms or in the privacy policy.Source: Harper Meds' website; Harper Meds' terms of service page; Harper Meds' privacy policy.

S6PASSNexus Health Solutions LLC at 945 W Side Ave, Jersey City, NJ 07306, printed in the privacy policy's contact block, with the same street given in the terms. The terms name Delaware law.Source: Harper Meds' privacy policy; Harper Meds' terms of service page.

S7PASSThe program starts at $149 a month, which the answers say covers the doctor consultation, prescription, medication and shipping with no additional fees. No separate price is printed for semaglutide or tirzepatide.Source: Harper Meds' website.

S8PASSFDA warning letter 728281, June 2026, names Nexus Health Solutions LLC doing business as Harper Meds at the Jersey City, New Jersey address its privacy policy prints, and it reviewed the seller's own website. It alleges that the pictured labels identify Harper Meds as the compounder, that the claim of the same active ingredient as Ozempic and Wegovy is false or misleading, and that the site called its compounding facilities FDA-licensed. No close-out letter appears in the index. No FDA action has halted the business, and the seller still trades.Source: FDA's website; FDA warning letter 728281.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide.

Other sellers of the same products

Who sells semaglutide Who sells tirzepatide

Enforcement documents on file: 1 warning letter

FDA warning letter 728281, issued June 2026, to Nexus Health Solutions LLC dba Harper MedsPictured labels identify Harper Meds as the compounder of semaglutide and tirzepatide products when it is not, the claim of the same active ingredient as Ozempic and Wegovy is false or misleading, and the site calls its compounding facilities FDA-licensed.

A warning letter alleges violations and requests a response. It does not halt a business, and it does not remove a seller from this ledger. Every letter recorded here.

Visit Harper Meds

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.